Purity Specifications, Storage and Distribution for Medications Development

The National Institute on Drug Abuse (NIDA) issued a sources sought notice on July 30, 2026, seeking capability statements from small businesses to establish a centralized repository for compounds used in medications development, with submissions due by August 14, 2026. This is a market research notice and does not commit the Government to any contractual award or compensation of respondents.

NIDA seeks in-house capability to inventory, analyze, and store approximately 10,000 chemical and biological compounds in quantities ranging from milligrams to several kilograms under non-GMP and GMP conditions. Storage requirements span room temperature to -80°C in inert, desiccated, and high-security atmospheres, including disposal of neurotoxins and biohazardous materials. The contractor must perform analytical testing including Thin Layer Chromatography, High Performance Liquid Chromatography, Mass Spectrometry, Gas Chromatography, Nuclear Magnetic Resonance, and Optical Rotation analysis with reporting to the Contracting Officer's Representative. Additional scope includes packaging and shipping compounds as blinded samples to domestic and international test sites, maintaining a secure web-based inventory and tracking system with daily updates and DEA compliance for scheduled substances, and purchasing commercially available compounds.

DEA Research Registration for Schedules II through V and potentially Schedule I controlled substances is mandatory. Capability statements must detail experience with similar projects, personnel qualifications including key scientists and technical staff, facility descriptions with available equipment, company name, UEI number, NAICS code 541715, and business size and status. Submissions go to polina.klimenkova@nih.gov with subject line "Capability Statement 75N98026R00136/N01DA-27-8961."